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OBJECTIVES We sought to find out whether G-protein-coupled receptor kinase (GRK) activity is also
increased in the aging human heart.
BACKGROUND In the aging and failing human heart, cardiac beta-adrenoceptors (beta-AR) are desensitized.
In heart failure (HF), an increase in cardiac GRK activity considerably contributes to this
beta-AR desensitization.
METHODS We assessed GRK activity (by in vitro rhodopsin phosphorylation) in the right atria (RA)
from 16 children (mean age 9  2 years) and 17 elderly patients (mean age 67  2 years)
without apparent HF and in the RA from four patients with end-stage HF.
RESULTS Cytosolic and membranous GRK activities in the RA from children were not significantly
different from those in elderly patients; in contrast, cytosolic and membranous GRK activities
in the RA from patients with end-stage HF were significantly increased.
CONCLUSIONS In contrast to the failing human heart, in the aging human heart, GRK activity is not
increased. Thus, GRK activity appears to not play an important role in beta-AR desensiti-
zation in the aging human heart. (J Am Coll Cardiol 2003;42:1487–92) © 2003 by the
American College of Cardiology Foundation
It is now generally accepted that with aging the functional
responsiveness of the human cardiac beta-adrenoceptor
(beta-AR) system decreases (1–3). In addition, we have
previously shown that not only beta-AR-mediated effects
but all effects mediated by cyclic adenosine monophosphate
(cAMP) are blunted in the aging human heart (4). Thus, in
this respect the aging human heart resembles the failing
human heart, since in chronic heart failure (HF) also all
effects mediated by cAMP are reduced (2,3). One important
mechanism that plays a significant role in cardiac beta-AR
desensitization in chronic HF is an increase in activity of
G-protein-coupled receptor kinase (GRK) that enzyme that
phosphorylates agonist-occupied receptors, and by this un-
couples receptors from the effector mechanism (3,5,6). This
increase in cardiac GRK activity appears to be due to
chronic activation of cardiac beta-ARs by the increased
sympathetic nervous system activity (6,7).
It has repeatedly been reported that with aging sympa-
thetic activity also increases (3,8,9). Thus, it might also be
true that, in the aging human heart, an increase in GRK
activity due to chronic beta-AR stimulation by increased
sympathetic activity might contribute to beta-AR desensi-
tization. To test this hypothesis, in this study we assessed
GRK activity in the right atria (RA) from patients of
different ages without apparent HF.
METHODS
Right atrial appendages. Right atrial appendages were
obtained from: 1) 16 children (9 males and 7 females; age 3
months to 21 years [mean 9  2 years]) with acyanotic
congenital heart disease who underwent open-heart surgery
because of a ventricular septal defect (n  7) or atrial septal
defect (n  9). Their parents had given informed, written
consent. None of the patients suffered from acute HF or had
been treated with sympathomimetics or sympatholytics for
at least three weeks before surgery; and 2) 17 adult patients
with coronary artery disease (9 males and 8 females; age 52
to 80 years [mean 67  2]) undergoing coronary artery
bypass grafting without apparent HF (New York Heart
Association [NYHA] functional class 0-I: n  3; NYHA
class II: n  14); their ejection fraction was 67  5%. All
patients gave written, informed consent before surgery.
None of these patients had been treated with sympathomi-
metics or sympatholytics for at least six weeks before
surgery. However, patients had received nitrates (n  6),
calcium antagonists (n  2), diuretics (n  4), hydroxy-
methylglutaryl coenzyme A reductase inhibitors (n  4),
acetyl salicylic acid (n  5), and occasionally digitalis
glycosides (n  1), alone or in combination.
Anesthesiologic premedication and surgery were carried
out exactly as recently described (4,10). Right atrial append-
ages were removed after installation of the cardiopulmonary
bypass. Immediately after excision, the specimen were
quickly frozen in liquid nitrogen and stored at 80°C until
further use. The study was approved by the local ethics
committees.
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In addition, right atrial myocardium was obtained from
four male patients with end-stage HF (mean age 51  4
years, NYHA class IV) due to ischemic (n  3) or dilated
cardiomyopathy (n  1), with an ejection fraction of 20 
3%, undergoing heart transplantation and from four organ
donors (3 males and 1 female; mean age 30  12 years)
whose hearts could not be used for transplantation.
Written, informed consent was obtained from a family
member; donor histories revealed no signs of HF.
Determination of GRK activity. The GRK activity was
assessed as recently described, with minor modifications
(11). Briefly, frozen tissue was thawed on ice in 5 ml
ice-cold lysis buffer (25 mmol/l Tris-HCl, 5 mmol/l
EDTA, and 5 mmol/l EGTA containing 40 g/ml leupep-
tin, 40 g/ml benzamidine, and 40 g/ml phenylmethane
sulfonyl fluoride). Fatty and connective tissue were carefully
removed, and 20 to 50 mg of the remaining tissue was
transferred into 1 ml lysis buffer, minced with scissors, and
homogenized with an Ultra-Turrax (Ultra-Turrax T25;
Janke & Kunkel IKA Labortechnik; Staufen, Germany) at
19,000 rpm for 60 s on ice.
Before centrifugation for 30 min at 50,000 g and 4°C, 10
l of a 5 mol/l NaCl solution (final concentration 50
mmol/l) was added, and the homogenate was incubated for
10 min on ice. After centrifugation, the supernatant (“cy-
tosolic GRK fraction”) was carefully removed and trans-
ferred into new reaction tubes, quickly frozen in liquid
nitrogen, and stored at 80°C until further use.
To detach membrane-associated GRK, the pellet was
re-suspended in 760 l lysis buffer  40 l 5 mol/l NaCl
solution (final concentration 250 mmol/l) with the Ultra
Turrax for 60 s at 9,500 rpm. After 15 min of incubation on
ice, the homogenate was re-centrifuged for 30 min at
50,000 g and 4°C. The supernatant (“membranous GRK
fraction”) was transferred into new reaction tubes, quickly
frozen into liquid nitrogen, and stored at 80°C until
further use. The protein concentration was determined
according to Bradford, with bovine gamma-globulin as
standard (12).
Twenty micrograms of cytosolic protein and 10 g of
membrane protein were mixed in duplicate in the dark at
4°C with 200 pmol rhodopsin (prepared from bovine
retina), 10 mmol/l MgCl2, 100 mol/l adenosine triphos-
phate (ATP), 180 pmol beta-gamma-subunits, and gamma-
32P-ATP (20 Ci  0.08 mmol/l) in a total volume of 60
l. Light-dependent phosphorylation of rhodopsin was
initiated by incubating samples under light for 10 min at
30°C. The reaction was terminated by the addition of 250
l ice-cold lysis buffer. Samples were immediately centri-
fuged for 10 min at 10,000 g at room temperature; the
supernatants were discarded and the pellets re-suspended in
30 l twice-concentrated Laemmli buffer by vigorous shak-
ing for 15 min at 30°C (13).
The samples were electrophoresed on 10% sodium dode-
cyl sulfate-polyacrylamide gels, which were stained with
Coomassie brilliant blue, according to Reissner et al. (14),
and autoradiographed. The rhodopsin bands (35 kd) were
cut off the gel, and their radioactivity was determined by
Cerenkov counting.
Determination of adenylyl cyclase (AC) activity. The AC
activity was assessed by a method repeatedly described in
detail elsewhere (4,15).
Statistical evaluations. The experimental data given in
text and figures are expressed as the mean value  SEM of
the number of patients. The significance of differences was
estimated by the nonpaired two-tailed Student t test. All
statistical calculations were performed with the Prism pro-
gram (Graph-Pad Software, San Diego, California). A p
value  0.05 was considered to be significant.
Drugs used. Both (alpha-32P)-ATP and (gamma-32P)-
ATP were purchased from NEN Life Science Products Inc.
(Boston, Massachusetts). Purified bovine rhodopsin and the
beta-gamma-subunits for the GRK assay were kindly pro-
vided by Prof. Dr. M. J. Lohse (University of Wu¨rzburg,
Germany). All other chemicals were of the highest purity
grade commercially available.
RESULTS
Right atrial GRK activity in young and elderly patients.
The GRK activity was measured in right atrial cytosol and
membranes by assessing their capacity to phosphorylate
light-activated rhodopsin. Cytosolic and membranous GRK
activities in the RA from children were not significantly
different from those in elderly patients. As demonstrated in
Figure 1, the GRK pool distribution (cytosolic/membranous
GRK activity ratio) was also not significantly different
between children (31.1  2%:68  2%) and elderly patients
(27.5  1.6%:72  1.6%).
To demonstrate that with our method we are able to
detect changes in GRK activity, we next assessed GRK
activity in the RA from patients with end-stage HF, as it is
well known that in these patients GRK activity is increased
(5). Cytosolic as well as membranous GRK activities were
significantly higher in failing versus non-failing atria, result-
ing in a slight but nonsignificant shift in the cytosolic/
membranous GRK activity ratio (23  1.6%:77  1.6% in
Abbreviations and Acronyms
AC  adenylyl cyclase
AR  adrenoceptor
ATP  adenosine triphosphate
cAMP  cyclic adenosine monophosphate
GRK  G-protein-coupled receptor kinase
GTP  guanosine triphosphate
HF  heart failure
NYHA  New York Heart Association
RA  right atria, right atrium
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failing vs. 27  1.2%:73  1.2% in non-failing RA, p 
0.092) (Fig. 2).
Adenylyl cyclase activity in young and elderly patients.
To demonstrate that in our study the right atrial beta-AR-
G-protein(s)-AC system differs between children and el-
derly patients, we finally assessed right atrial AC activity. In
agreement with our recently published data (4,15), we found
that in atrial membranes from children, basal AC activity, as
well as 10 mol/l guanosine triphosphate (GTP)-, 10
mol/l isoprenaline-, and 10 mol/l forskolin-stimulated
AC activity, was significantly higher than in atrial mem-
branes from elderly patients (Fig. 3).
DISCUSSION
The main finding of this study was that cardiac GRK
activity was not different in the RA from children or elderly
patients; however, it was significantly increased in the RA
from end-stage failing hearts versus non-failing hearts, in
agreement with the literature (3,5,6).
Beta-ARs are desensitized in the aging human heart. It
is well known that with aging, the cardiac beta-AR-G-
protein(s)-AC system declines. We have previously shown
that in the RA of patients with an age range very similar (7
days to 83 years) to that in the present study, there was a
Figure 1. (A) Typical autoradiopraph of light-dependent in vitro phos-
phorylation of rhodopsin (32P-ROS) by atrial cytosolic (CYT) and mem-
branous (MEM) GRK obtained from a child (3-year-old male; NYHA
class 0) and an elderly patient (60-year-old male; NYHA class I). (B) Bar
graph showing cytosolic and membranous GRK activity in right atrial
appendages obtained from 10 children (5 males and 5 females; mean age 6
 2 years [range 3 months to 20 years]; NYHA class 0.9  0.3) and eight
elderly patients (4 males and 4 females; mean age 68  3 years [range 59
to 80]; NYHA class 1.9  0.4). Activities were calculated as 32P
incorporated in rhodopsin in cpm  103 per mg protein. Data are given as
the mean value  SEM.
Figure 2. (A) Typical autoradiopraph of light-dependent in vitro phos-
phorylation of rhodopsin (32P-ROS) by cytosolic (CYT) and membranous
(MEM) GRK obtained from the RA from a non-failing (3-year-old male
donor; NYHA class 0) and failing (61-year-old male recipient; NYHA
class IV) heart. (B) Bar graph showing cytosolic and membranous GRK
activity in right atrial appendages obtained from four non-failing (mean age
30  12 years [range 3 to 52]; 3 males and 1 female; NYHA class 0) and
four failing (mean age 51  4 years [range 44 to 63]; 4 males; NYHA class
IV) hearts. Activities were calculated as 32P incorporated in rhodopsin in
cpm/mg protein. Data are given as the mean value  SEM. *p  0.0381
vs. non-failing heart.
Figure 3. Adenylyl cyclase activity in right atrial appendages obtained from
six children (4 males and 2 females; mean age 13  3 years [range 4 to 21];
open columns) and nine elderly patients (5 males and 4 females; mean age
66  3 years [range 52 to 78]; solid columns). Data are given as the mean
value  SEM. *p  0.05 vs. children. B  basal; GTP  10 mol/l
guanosine triphosphate; ISO 10 mol/l isoprenaline; FOR 10 mol/l
forskolin.
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significantly negative correlation between the age of the
patients and AC activity. This held true not only for
beta-AR-activated AC but also for GTP-, histamine- (via
H2 receptors), serotonin- (via 5-HT4 receptors), forskolin-,
and Mn2-activated AC (Fig. 3) (4,15), indicating that
with age, the activity of the catalytic unit of AC decreased.
This was accompanied by a slight but significant increase in
Gi proteins, which might contribute to the decline in AC
activity (4). Accordingly, in electrically driven right atrial
trabecular preparations of these patients, the potency of
isoprenaline to increase the force of contraction was about
10-fold higher in the atria from young versus old patients; in
these atria, however, the beta-AR density was only margin-
ally altered (4). Similar data of a decreased beta-AR-
mediated activation of AC and the inotropic potency of
isoprenaline were also obtained in ventricular preparations
of the aging human heart (16–18). However, in ventricular
myocardium, the beta-AR density and Gs protein were
found to decrease with age, whereas the Gi protein was
unchanged (18). The reason for these (tissue-specific?)
differences between the aging atrial and ventricular human
myocardium is not known; however, the functional conse-
quence in both tissues is a blunting of beta-AR-mediated
effects and all other cAMP-dependent effects with aging. In
this respect, the aging human heart resembles the failing
human heart, which also exhibits a markedly reduced
responsiveness of beta-AR stimulation and all other cAMP-
mediated effects (2,3). However, it should be emphasized
that decreases in beta-AR and the accompanying increase in
Gi protein are markedly more pronounced in the failing
human heart than they are in the aging human heart (2–4).
Activity of GRK is not altered in the aging human
heart. One important factor that contributes to beta-AR
desensitization in failing human hearts is an increase in the
activity of cardiac GRK (Fig. 2) (3,5,6). G-protein-coupled
receptor kinase phosphorylates the agonist-occupied recep-
tor, thereby facilitating binding of arrestin to the phosphor-
ylated receptor. This leads to uncoupling of the receptor
from the Galpha-s-AC system and finally to a decrease in the
beta-AR response to agonist stimulation. Chronic beta-AR
stimulation is a strong trigger mechanism to increase GRK
activity (19). In aging, sympathetic activity is also increased,
thus leading to chronic stimulation of beta-ARs (8,9).
Therefore, also in the aging human heart, an increase in
GRK activity might contribute to cardiac beta-AR desen-
sitization. However, the present data clearly show that this
is not the case. The activity of neither cytosolic nor
membranous GRK was significantly altered in the aging
human RA as compared with the atria from children. It
should be noted that we recently have shown in several
studies that age-dependent differences in the cardiac auto-
nomic receptor systems are more pronounced when data
obtained in children are compared with those obtained in
elderly patients (60 years) than when comparing data of
middle-aged patients (20 to 40 years) versus elderly patients
(60 years) (4,10,15). Therefore, we are quite sure that
because of the lack of difference in GRK activity between
children and elderly patients (60 years) in this study, there
is no age-dependent alteration in GRK activity in the
human heart. Moreover, the fact that we found a significant
increase in GRK activity in the RA from end-stage failing
hearts versus non-failing hearts (as to be expected from the
published data) makes it unlikely that we might have
overlooked changes in the aging heart. This is further
supported by the fact that in the present study we found the
well-known decreased activity of basal as well as 10 mol/l
GTP-, 10 mol/l isoprenaline-, and 10 mol/l forskolin-
stimulated AC in the atrial membranes from elderly patients
versus children (4,15).
The reasons for the differences in GRK’s regulation in the
aging versus failing human heart are not completely under-
stood at present. However, it should be considered that, in
aging, the increase in sympathetic activity develops slowly
and moderately, as indicated by the observation that plasma
noradrenaline levels (often taken as an indirect index of
sympathetic activity) (20) increase continuously 10% to 15%
per decade due to enhanced spillover of noradrenaline into
the circulation (21,22). Thus, with aging, plasma noradren-
aline levels are increased up 300 to 600 pg/ml (9,23). In
chronic HF, on the other hand, increases in sympathetic
activity occur much more rapidly and are more pronounced
than in the aging heart (24). Thus, plasma noradrenaline
reaches within a rather short time (compared with aging)
levels between 600 and 1300 pg/ml (24,25). The GRKs,
however, exclusively mediate receptor-specific uncoupling
in response to prolonged high concentrations of agonists
(26,27). Thus, the time course and intensity of increases in
sympathetic activity differ between the aging and failing
human heart, and these differences might be a possible
explanation for the different regulation of GRKs in the
aging and failing human heart.
To the best of our knowledge, this is the first study on
possible age-dependent changes in GRK activity in the
human heart. However, there was a recent study of the rat
heart that also failed to find any age-dependent alterations
in cardiac GRK2 or GRK5 activity (28).
In the heart, three isoforms of GRK are expressed:
GRK2, GRK3, and GRK5, whereby GRK2 is the most
abundant form (3,6,7). Moreover, GRK isoforms phos-
phorylate rhodopsin with the relative order of potency:
GRK2  GRK3  GRK5 (29).
Whereas GRK2 and GRK3 activation invariably involves
a translocation from the cytosol to the cell membrane (30),
which is targeted for GRK2 by G-protein beta-gamma-
subunits, GRK5 seems to rest constitutively in the mem-
brane and does not undergo translocation (31). In the
present study, we found increases in GRK activity only in
the cytosol and membranes of the failing human heart;
whether this is the sum of changes in different GRKs or just
an increase in cytosolic and membrane-translocated GRK2
we cannot decide from the present experiments, because the
phosphorylation assay used in this study cannot distinguish
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between the individual subtypes. On the other hand, GRK
activity was not changed in either the cytosol or membranes
of the aging human heart. Thus, although we cannot
exclude the possibility that induction of other GRKs like
GRK3 or GRK5, which appear to be unaltered in the failing
human heart (6,32), might contribute to the regulation of
cytosolic and membranous GRK activity, as assessed in the
present study, it is very likely that with our method we have
assessed predominantly the activity of right atrial GRK2,
and this is increased in the failing and unchanged in the
aging human heart.
Study limitations. In this study, we have tried to find
age-dependent changes in children versus elderly patients.
Children were quite young (mean age 9 years). At this age,
many children were prepubertal, and hence, maturation
processes are not finished. In addition, patients were not
completely normal but had a mild cardiac diagnosis (NYHA
class of the group of elderly patients was II), which also
might have affected our data. We cannot exclude that these
facts might have contributed to the lack of age-dependent
differences in GRK activity, but it will be rather impossible
to obtain tissue samples from really normal human hearts
with a more appropriate age distribution. However, in
patients with a very similar etiology and age distribution, we
have recently found significant correlations between age and
right atrial AC activity (4), age and right atrial muscarinic
receptors (15), and age and right atrial noradrenaline re-
uptake transporter (uptake1) (10). These findings strongly
favor the idea that, in this study, there is indeed a lack of
age-dependent changes in right atrial GRK activity.
In addition, in the present study, the lack of age-
dependent changes in GRK activity was assessed in the
human RA. Whether this also holds true for human left
ventricular GRK activity is not known. It should be men-
tioned that changes in the beta-AR system observed in the
human RA can or cannot be identical to those in human
ventricular myocardium. Thus, in end-stage HF, beta-ARs
were markedly decreased in right atrial and left ventricular
preparations of the human heart (33). On the other hand, as
discussed earlier in this report, age-dependent changes in
beta-ARs appear to be different between atrial (4) and
ventricular myocardium (18). However, in the present
study, we have found increased GRK activity in the RA
from patients with end-stage HF (Fig. 2), and similar GRK
increases also occur in the ventricular myocardium of
patients with end-stage HF (5,32). This also might be taken
as an indication that in the ventricular myocardium of the
aging human heart GRK activity is not altered, although the
final experimental proof is lacking.
Conclusions. In the aging human heart, GRK activity
(presumably GRK2) is not altered, in contrast to the failing
human heart, where GRK2 is significantly increased. Thus,
increased GRK2 activity seems not to contribute to the
beta-AR desensitization observed in the aging human heart.
Although there are some similarities between the aging and
failing human heart, in this respect, the aging human heart
is clearly different from the failing human heart.
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